Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levelsMay 11, 2012
Barcelona, Spain: Patients with head and neck cancer and a low haemoglobin (Hb) level do not respond well to radiotherapy and therefore both control of their tumour and disease-free survival are compromised. Now researchers from The Netherlands have found that the problems caused by low Hb in these patients can be overcome by the use of a treatment known as ARCON therapy, in which accelerated radiotherapy is combined with carbogen (a mixture of carbon dioxide and oxygen) and the water-soluble vitamin nicotinamide .
Hans Kaanders, a professor of translational radiation oncology at Radboud University Nijmegen Medical Centre, Nijmegen, will tell the 31st conference of the European Society for Radiotherapy and Oncology  today (Friday) that the ARCON regime is the first to show a positive effect in patients with low Hb levels.
The researchers recruited 345 patients with squamous cell laryngeal cancer to a randomised trial: 174 received only accelerated radiotherapy (where two fractions per day are administered during the last week of radiotherapy in order to reduce the overall length of treatment), and 171 ARCON. Patients receiving ARCON inhaled carbogen during radiotherapy and took nicotinamide tablets prior to treatment. Pre-treatment Hb levels in the experimental group were measured and subsequently compared with the treatment outcomes in the accelerated radiotherapy alone arm.
They found that patients treated with accelerated radiotherapy alone who had normal Hb levels before treatment had significantly better control of the cancer at its primary site (76% as opposed to 56%), disease-free survival (72% and 48% respectively), and metastasis-free survival (90% and 70%) than those with low Hb levels.
"However, when we looked at the ARCON group, in cases where the patients had low Hb levels before treatment, we found that ARCON improved control of the cancer at its primary site, and improved disease-free and metastasis-free survival, so that the differences between them and patients with normal Hb levels were no longer significant," says Professor Kaanders' colleague Dr. Geert Janssens. The difference in local control between this low Hb group and the normal Hb accelerated radiotherapy (AR) alone group was only 1% (81% in the ARCON group versus 82% in the AR-only group); for disease-free survival, the difference was 77% (ARCON) as opposed to 70% (AR); and for metastasis-free survival 93% (ARCON) versus 89% (AR).
However, patients in both groups with low Hb levels pre-treatment still had a worse overall survival irrespective of which treatment they received. This is most likely due the fact that many patients with head and neck cancer also have other health problems that cannot be treated by radiotherapy, the researchers say.
"In the past, a number of investigators have tried to improve the outcome for patients with low Hb levels by giving erythropoietin, which stimulates red blood cell production, and red cell blood transfusion before and during treatment, but without success. ARCON is the first treatment to be found to correct for low Hb and therefore to improve prognosis in these patients," says Dr. Janssens. "We know that a decrease in Hb levels is associated with a reduced sensitivity to radiotherapy, and that this can switch the tumour microenvironment into a more aggressive subtype with a higher risk of loco-regional failure and of the development of distant metastases."
The lack of success with transfusion of red blood cells or erythropoietin suggests underlying adaptive mechanisms. Accelerated radiotherapy to counteract tumour cell repopulation during radiotherapy, combined with carbogen and nicotinamide, administered immediately before irradiation to increase the oxygen level, ensures that adaptive mechanisms cannot erode the effect, and this is probably the key to success of the ARCON regime in patients with low HB levels at presentation, the researchers say.
"We believe that, at a time when healthcare systems are under increasing pressure to introduce expensive targeted treatments, the use of such a low cost, effective therapy should only be encouraged," Professor Kaanders will conclude.
Prof Vincenzo Valentini, radiation oncologist at the Policlinico Universitario A. Gemelli in Rome, Italy, and President of ESTRO, said: "We know that the degree of oxygenation of tumours in laryngeal cancer patients is directly related to the damage that can be caused to them by radiotherapy. This important study shows that, in patients with low haemoglobin levels, it is possible to reoxygenate the tumour by using the simple and cost-effective ARCON regime, and therefore increase the effectiveness of radiation treatment."
Abstract no: OC 217, 10.30 hrs, Friday 11 May, Auditorium
 When carbogen is inhaled, the increased level of carbon dioxide causes the brain to react to potential suffocation because it interprets the increase in blood carbon dioxide as a decrease in oxygen level, and the body compensates by reducing hypoxia. Nicotinamide also reduces hypoxia by increasing blood flow.
 This year the ESTRO conference is held in parallel with the World Congress of Brachytherapy, both taking place in Barcelona from May 9-13.
European Society for Radiotherapy and Oncology (ESTRO)
Related Radiotherapy Current Events and Radiotherapy News Articles
More intensive radiotherapy is better than less for localized prostate cancer
A radiotherapy regime involving higher doses of radiation is a better option than having lower doses for men with localised prostate cancer, the 10-year results of the largest trial of its kind have shown.
Pancreas cancer is notoriously impervious to treatment and resists both chemotherapy and radiotherapy.
Pancreas cancer is notoriously impervious to treatment and resists both chemotherapy and radiotherapy. It has also been thought to provide few targets for immune cells, allowing tumors to grow unchecked.
Humidification of the mouth, throat during RT for head and neck cancer reduces mucositis, hospital stay
Patients who received daily humidification of the mouth and throat region beginning from day one of radiation therapy treatment spent nearly 50 percent fewer days in the hospital to manage their side effects.
Hypnosis therapy shown to decrease fatigue levels in breast cancer patients
Breast cancer patients receiving radiotherapy showed decreased fatigue as a result of cognitive behavioral therapy plus hypnosis (CBTH), according to a study recently published in the Journal of Clinical Oncology.
A promising new approach for treating leukemia discovered
A group of researchers at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression.
Skin reactions during radiation therapy preventable
Severe skin reactions during radiation therapy could be prevented by applying a thin transparent silicone dressing to the skin from the first day of treatment, clinical research from New Zealand shows.
Prostate cancer advance could improve treatment options
Researchers at the University of East Anglia have made an important advance in understanding genetic changes associated with terminal prostate cancer.
Engineered virus is effective against triple negative breast cancer cells
Scientists have discovered a potential cure for one of the most aggressive and least treatable forms of breast cancer called "triple negative breast cancer."
'Weeding the garden' with radiation allows ALK+ lung cancer patients to continue crizotinib, increasing survival
A University of Colorado Cancer Center study published today in the International Journal of Radiation Oncology Biology and Physics shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease.
Breast cancer in young women after treatment for Hodgkin's disease
Girls treated for Hodgkin's disease during adolescence acquire a considerable risk of developing breast cancer, as shown by an observational study published in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2014; 111 (1-2): 3-9).
More Radiotherapy Current Events and Radiotherapy News Articles